CAR T cells produced in vivo to treat cardiac injury

Joel G. Rurik; István Tombácz; Amir Yadegari; Pedro O Méndez Fernández; Swapnil V. Shewale; Li Li; Toru Kimura; Ousamah Younoss Soliman; Tyler E. Papp; Ying K. Tam; Barbara L. Mui; Steven M. Albelda; Ellen Puré; Carl H. June; Haig Aghajanian; Drew Weissman; Hamideh Parhiz; Jonathan A. Epstein; Joel G. Rurik; István Tombácz; Amir Yadegari; Pedro O Méndez Fernández; Swapnil V. Shewale; Li Li; Toru Kimura; Ousamah Younoss Soliman; Tyler E. Papp; Ying K. Tam; Barbara L. Mui; Steven M. Albelda; Ellen Puré; Carl H. June; Haig Aghajanian; Drew Weissman; Hamideh Parhiz; Jonathan A. Epstein

doi:10.1126/science.abm0594

Abstract

Making CAR T cells in vivo Cardiac fibrosis is the stiffening and scarring of heart tissue and can be fatal. Rurik et al . designed an immunotherapy strategy to generate transient chimeric antigen receptor (CAR) T cells that can recognize the fibrotic cells in the heart (see the Perspective by Gao and Chen). By injecting CD5-targeted lipid nanoparticles containing the messenger RNA (mRNA) instructions needed to reprogram T lymphocytes, the researchers were able to generate therapeutic CAR T cells entirely inside the body. Analysis of a mouse model of heart disease revealed that the approach was successful in reducing fibrosis and restoring cardiac function. The ability to produce CAR T cells in vivo using modified mRNA may have a number of therapeutic applications. —PNK

Affiliated Institutions

Related Publications

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Stephan A. Grupp , Michael Kalos , David M. Barrett +10 more

Chimeric antigen receptor-modified T cells with specificity for CD19 have shown promise in the treatment of chronic lymphocytic leukemia (CLL). It remains to be established whet...

2013 New England Journal of Medicine 3403 citations

Molecular and cellular mechanisms of liver fibrosis and its regression

Tatiana Kisseleva , David A. Brenner

Chronic liver injury leads to liver inflammation and fibrosis, through which activated myofibroblasts in the liver secrete extracellular matrix proteins that generate the fibrou...

2020 Nature Reviews Gastroenterology & Hep... 1655 citations

Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis.

P F Piguet , C Ribaux , Vildan Karpuz +2 more

The expression of tumor necrosis factor alpha and its mRNA was investigated in surgical biopsies from idiopathic pulmonary fibrosis by immunohistochemistry, in situ hybridizatio...

1993 PubMed 189 citations

CAR-T cell therapy: current limitations and potential strategies

Robert C. Sterner , Rosalie M. Sterner

Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses ...

2021 Blood Cancer Journal 2373 citations

Phenotypically distinct subsets of CD4<sup>+</sup> T cells induce or protect from chronic intestinal inflammation in C. B-17 <i>scid</i> mice

Fiona Powrie , Michael W. Leach , Smita Mauze +2 more

CD4+ T cells in the mouse can be subdivided into two fractions based on the level of expression of the CD45RB determinant. Previous studies have shown that these subsets are fun...

1993 International Immunology 1061 citations

Publication Info

Year: 2022
Type: article
Volume: 375
Issue: 6576
Pages: 91-96
Citations: 993
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

CAR T cells produced in vivo to treat cardiac injury

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

993

OpenAlex

Cite This

APA Style

                            
                                
                                    Joel G. Rurik, 
                                
                                    István Tombácz, 
                                
                                    Amir Yadegari
                                
                                et al.
                            
                            (2022). 
                            CAR T cells produced in vivo to treat cardiac injury. 
                            Science
                            , 375
                            (6576)
                            , 91-96.
                            https://doi.org/10.1126/science.abm0594
                        

Identifiers

DOI: 10.1126/science.abm0594